SynthesisAnnals of surgical oncology2026
Impact of R0/R1 Margin Status on Overall Survival in Node-Positive Resected Pancreatic Ductal Adenocarcinoma: Meta-Analysis.
Synthesis in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroscopic residual disease (R1)and node-positive disease in resected pancreatic ductal adenocarcinoma (PDAC) are associated with worse survival. Some have suggested that obtaining an R0 resection is no longer relevant when patients have node-positive disease. A meta-analysis confirming this hypothesis is lacking. PATIENTS AND
methodsA systematic review including studies with at least 50 patients with resected node-positive PDAC was conducted in PubMed, Embase, and Web of Science (inception to March 2025). Patients with node-negative disease were excluded. Primary outcome was overall survival (OS), comparing R0N+ and R1N+ resections. Hazard ratios (HR) with 95% confidence intervals (CI) represented outcome measures. Subgroup analysis included: application of the Royal College of Pathology protocol (RCP: standardized margin inking, axial slicing, and "1-mm rule") and receipt of neoadjuvant/adjuvant therapy.
resultsOverall, 19,206 patients with resected node-positive PDAC from 16 retrospective studies were included. Most patients underwent upfront resection (96.3%), primarily pancreatoduodenectomy (84.2%). The overall R0N+ rate was 61.1%, differing significantly by application of RCP (yes [R1 = tumor within 1 mm of margin]: nine studies, 52.1%; unclear: four studies, 80.5%; no [R1 = tumor at margin ink only]: three studies, 61.5%; p = 0.0019). Overall, R1 negatively impacted OS (HR: 1.38; 95% CI: 1.21-1.59). RCP-only subgroup analysis confirmed worse OS in R1N+ resections (HR 1.25; 95% CI 1.10-1.42). Subgroup analysis by neoadjuvant/adjuvant therapy was not feasible.
conclusionsAmong patients with node-positive PDAC treated with upfront surgery, R1 resection remains associated with worse survival. In these patients, R0 resection should not be dismissed as a viable treatment goal until stronger RCP-compliant evidence emerges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.